| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2013042053 |
| Title |
Compounds for Use In The Treatment of Alzheimer'S Disease. |
| Abstract |
The invention relates to a method of modulating concentration of Alzheimer's Disease (AD) relevant proteins amyloid precursor protein (APP), beta (gama) and gamma (gama) secretases and amyloid beta peptide (Agama), and also relates to a method of reducing Agama shedding. Furthermore, this invention extends to a compound for use in the treatment of AD, and also to a method of treating AD. |
| Applicant(s) |
University of the Witwatersrand, Johannesburg |
| Representative Drug(s) |
D02DOE |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2005035580 |
| Title |
Single-Chain Antibody Acting Against 37 Kda/67 Kda Laminin Receptor As Tools for The Diagnosis and Therapy of Prion Diseases and Cancer, Production and Use Thereof. |
| Abstract |
The invention relates to single-chain antibodies which specifically detect the 37 kDa precursor form of the laminin receptor (37 kDa LRP) and also the 67 kDa high-affinity form of the laminin receptor (67 kDa LR), in addition to pharmaceutical and diagnostic compositions containing said single-chain antibodies. |
| Applicant(s) |
Weiss Stefan |
| Patent ID |
WO2006105954 |
| Title |
Use of An Antibody Against The Laminin Receptor or Laminin Receptor Precursor for The Treatment or Diagnosis of Several Cancer Types. |
| Abstract |
Use of an antibody against the laminin receptor or laminin receptor precursor for the treatment of various cancers. Described is the use of a recombinant antibody comprising a binding site specific for an epitope of the laminin receptor or laminin receptor precursor for the treatment or diagnosis of various cancers, particularly B-CLL. Preferably, this antibody additionally comprises a binding site for at least one particular cell surface antigen. |
| Applicant(s) |
Affimed Therapeutics Ag |
